Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 24;9(12):3026-3030.
doi: 10.1182/bloodadvances.2025015981.

Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma

Joshua N Gustine  1 , Andrew R Branagan  1 , Diana D Cirstea  1 , Farah Rexha  1 , Ryan Han  1 , Andrew J Yee  1 , Marcela V Maus  1 , Matthew J Frigault  1 , Noopur S Raje  1
Affiliations

Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma

Joshua N Gustine et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: A.J.Y. has been a consultant for AbbVie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Johnson & Johnson (Janssen), Karyopharm, Oncopeptides, Pfizer, Prothena, Regeneron, Sanofi, Sebia, and Takeda; and has received research funding to the institution from Amgen, Bristol Myers Squibb, GlaxoSmithKline, Johnson & Johnson (Janssen), and Sanofi. M.V.M. is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital (some licensed to ProMab and Luminary) and University of Pennsylvania (some licensed to Novartis); receives grant/research support from Kite Pharma, Moderna, and Sobi; holds equity in 2Seventy Bio, A2 Bio, AffyImmune, BendBio, Cargo, GBM newco, Model T bio, Neximmune, and Oncternal; serves on the board of directors for 2Seventy Bio; and is or has been a consultant for A2 Bio, Adaptimmune, AffyImmune, Bristol Myers Squibb, Cabaletta, Cargo, In8bio, GlaxoSmithKline, Kite Pharma, Neximmune, Novartis, Oncternal, and Sobi. M.J.F. has been a consultant for Kite, Bristol Myers Squibb, Johnson & Johnson/Legend, and Novartis. N.S.R. received research funding and/or consulting fees from AbbVie, Bristol Myers Squibb, Caribou, GlaxoSmithKline, Immuneel, Janssen, K36 Therapeutics, Pfizer, and Sanofi. The remaining authors declare no competing financial interests.

References

    1. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726–1737. - PMC - PubMed
    1. Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716. - PubMed
    1. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002–1014. - PubMed
    1. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–324. - PubMed
    1. San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335–347. - PubMed